GHK-Cu Fragment Preclinical

What It Is

"GHK-Cu Fragment" is vendor shorthand for the copper-free form of glycyl-L-histidyl-L-lysine (GHK) — the tripeptide Gly-His-Lys without its copper(II) ion coordination partner. The "fragment" nomenclature is slightly misleading because the peptide sequence itself is the same three amino acids (Gly-His-Lys) as the parent GHK-Cu. What is actually missing is the copper ion that the parent peptide chelates with extraordinary affinity (log cK_7.4 ≈ 12.62) under physiological conditions (Trapaidze et al. 2012, J Biol Inorg Chem). Different vendors variously market the same product as "GHK Basic," "free GHK," "copper-free GHK," or "apo-GHK."

The GHK sequence was originally isolated from human plasma albumin in 1973 by Loren Pickart, then at the University of California, San Francisco, who identified it as a small tripeptide that promoted the growth of cultured hepatoma cells and prolonged the survival of normal hepatocytes (Pickart and Thaler, Nat New Biol 1973;243:85-87). Subsequent work showed that under physiological conditions the tripeptide rapidly binds Cu²⁺ to form the GHK-Cu complex, and the copper-bound form has since dominated research and commercial development. The 1988 Maquart et al. FEBS Letters paper that first demonstrated collagen-stimulating activity in fibroblast cultures explicitly used the copper complex, and the bulk of subsequent research has continued to use that form.

The case for studying GHK without copper became scientifically interesting in the late 2000s when Choi et al. (J Pept Sci 2012) reported in human skin-equivalent models that the copper-free tripeptide retained meaningful biological activity — specifically, a stem-cell-preserving effect mediated through fibroblast-keratinocyte growth-factor signaling, even in the absence of bound copper. A subsequent body of work has shown that GHK alone has radical-scavenger antioxidant activity (Cebrián-Torrejón et al. 2018), sequesters lipid-peroxidation byproducts such as 4-HNE and acrolein through direct histidine-residue chemistry (Beretta et al. 2007, 2008), and modulates a meaningful number of human genes via mechanisms that do not strictly require its bound copper. The implication: GHK and GHK-Cu share overlapping but non-identical biological profiles, and the copper-free form may have application contexts where copper supplementation is unwanted or where the application vehicle makes a non-chelating form preferable.

Practically, "GHK-Cu Fragment" is sold by research-chemical and peptide vendors as a less-expensive sibling product to the well-established GHK-Cu copper-peptide complex. The two should not be assumed interchangeable. Users selecting between them should understand that the copper-free form has thinner published evidence, that biological activity overlaps but is not identical, and that under physiological conditions a copper-free GHK injected SubQ will likely encounter and bind some endogenous copper within minutes — meaning the in-vivo distinction between "GHK" and "GHK-Cu" blurs rapidly after administration.

Mechanism of Action

The mechanism question is genuinely interesting because GHK and GHK-Cu have partially overlapping and partially distinct activity profiles. The proposed mechanism for the copper-free form draws on two literatures: (1) GHK as a metal-binding chelator / scavenger in its own right, and (2) GHK as a direct cellular signal that engages keratinocyte and fibroblast pathways without strictly requiring its copper partner.

• Copper sequestration vs copper delivery — The parent GHK-Cu form is best understood as a copper-delivery vehicle: the tripeptide chelates Cu²⁺ in the extracellular space and traffics it across membranes for downstream activation of copper-dependent enzymes (lysyl oxidase, superoxide dismutase, tyrosinase). The copper-free form, when administered, behaves like a copper sequestrant: it binds endogenous Cu²⁺ rather than delivering exogenous copper. At small doses the net effect on local copper homeostasis is therefore opposite to the parent.
• Direct antioxidant / radical-scavenger activity (copper-independent) — Cebrián-Torrejón et al. (2018, PMC6055086) demonstrated that free GHK quenches hydroxyl (·OH) and peroxyl (ROO·) radicals at low micromolar concentrations in living cells. The chemistry does not require bound copper and is sequence-specific to GHK rather than to its copper complex.
• 4-HNE and acrolein sequestration (copper-independent) — Beretta et al. (Chem Res Toxicol 2007; J Pharm Biomed Anal 2008) showed that GHK's histidine residue directly conjugates with 4-hydroxy-2-nonenal (4-HNE) and acrolein — toxic byproducts of membrane lipid peroxidation. The reaction does not require copper and mirrors the aldehyde-scavenging chemistry of the dipeptide carnosine.
• Skin stem-cell and basal-cell preservation (Choi 2012) — In human skin-equivalent models, copper-free GHK applied topically maintained the p63-positive basal stem-cell population, reduced UV-induced damage, and restored fibroblast-keratinocyte interaction-dependent growth-factor signaling. Proposed mechanism: fibroblast-derived growth-factor signaling rather than direct copper-dependent collagen synthesis.
• Gene-expression modulation (partially shared with GHK-Cu) — Pickart and Margolina (2014, 2015, 2018) report that GHK modulates expression of large gene sets in cultured cells — up to >4,000 genes in Connectivity Map-style analyses — with broad upregulation of DNA-repair, antioxidant, regeneration, and matrix genes. A fraction of these changes are copper-dependent; others are not. Independent replication outside Pickart's group is thin.
• Anxiolytic / CNS activity in rodents (Bobyntsev group) — A series of Russian papers (Bobyntsev and colleagues, Russian Academy of Medical Sciences) has shown parenteral GHK produces anxiolytic, neurotransmitter-modulatory, and cognitive effects in rodents. D-amino-acid replacement of the histidine or lysine attenuates activity, indicating sequence specificity. Mechanism unresolved; likely independent of the copper-binding axis.
• Divergence from GHK-Cu — fibroblast collagen stimulation — In head-to-head fibroblast collagen-synthesis assays, GHK-Cu consistently outperforms the copper-free tripeptide. This is the cleanest case where the two forms diverge pharmacologically and argues against using copper-free GHK alone where fibroblast collagen stimulation is the primary goal.
• In-vivo copper coordination is effectively certain — GHK's copper-binding affinity is high enough that, after parenteral administration, substantial in-vivo copper coordination is essentially inevitable. The "copper-free" distinction is most meaningful at the pre-administration product level; less so in the recipient's tissue.

What the Research Shows

Research specific to the copper-free form — as distinct from GHK-Cu — is thinner but not empty. Key findings:

• Skin stem-cell preservation (Choi 2012) — In human skin-equivalent cultures, copper-free GHK preserved p63-positive basal stem cells, reduced UV-induced damage, and restored fibroblast-keratinocyte growth-factor signaling. Foundational paper for the "GHK without copper still does meaningful things" hypothesis (J Pept Sci 2012;18(11):685-690).
• Antioxidant activity in living cells (Cebrián-Torrejón 2018) — Demonstrates copper-independent hydroxyl- and peroxyl-radical quenching by free GHK in living systems. Provides clear mechanistic basis for one therapeutic action that does not depend on copper.
• 4-HNE / acrolein sequestration (Beretta 2007, 2008) — Direct histidine-residue conjugation with reactive aldehydes, removing toxic lipid-peroxidation byproducts. Copper-independent.
• Gene-expression modulation (Pickart and Margolina, 2014, 2015, 2018) — Microarray analyses of GHK-treated cells (with and without copper) report modulation of thousands of genes toward a "younger" expression profile. Anti-aging gene signatures include DNA repair, antioxidant, and regeneration pathway upregulation and inflammatory / tumor-promoting pathway downregulation.
• Anti-cancer gene-expression signal (Pickart 2014, J Anal Oncol) — Reported GHK-induced expression of pro-apoptotic caspase, growth-regulatory, and DNA-repair genes. Whether the copper-free form replicates every gene-level effect of GHK-Cu has not been dissected.
• Anxiolytic activity in rodents (Bobyntsev group) — Multiple papers from the Bobyntsev group show parenteral free GHK produces anxiolytic activity and influences neurotransmitter systems. Sequence-specific (D-amino-acid substitutions attenuate activity). Western replication is thin; protocols are heterogeneous.
• Hair-follicle stimulation (mostly GHK-Cu) — Reported in cultured follicle models for both GHK and GHK-Cu. Whether copper-free GHK retains the full hair-growth signal in human use has not been tested in a controlled trial.
• Cosmetic ingredient evidence (dominated by GHK-Cu) — Placebo-controlled topical cosmetic facial studies (Abdulghani 1998; Leyden 2002) use the copper-bound form. Do not directly transfer to copper-free GHK product claims.
• What is absent — No published human clinical trial of injected or systemically dosed copper-free GHK. No head-to-head efficacy comparison vs GHK-Cu in matched human applications. No formal human pharmacokinetic data for either form.

Human Data

There is no published clinical trial of injected or systemically dosed copper-free GHK in humans. The published human evidence base for the GHK family sits on topical GHK-Cu cosmetic studies, none of which directly apply to parenteral copper-free GHK use.

• Topical GHK-Cu cosmetic studies — Multiple placebo-controlled 12-week facial cosmetic studies have reported anti-aging benefits of topical GHK-Cu cream / serum. All used the copper-bound form.
• No registered trial of copper-free GHK — A search of ClinicalTrials.gov for "copper-free GHK," "free GHK," or "apo-GHK" returns no registered trials as of April 2026.
• No published human PK data — Neither GHK nor GHK-Cu has been formally characterized for human pharmacokinetics after parenteral administration in peer-reviewed literature.
• Anecdotal SubQ and oral community use — Forum and practitioner reports describe SubQ injection of GHK (typically near hairline for hair growth, abdominal SubQ for systemic effect) and occasional oral / sublingual use. These are uncontrolled, selection-biased, and frequently confounded by concurrent skincare or other peptides.
• Practical implication — Anyone using copper-free GHK by injection or systemic route is operating outside the published human evidence base entirely. The bar for clinician supervision is correspondingly higher.

Dosing from the Literature

No human dose-finding study has been performed for copper-free GHK specifically. Community-typical doses below are extrapolated from GHK-Cu protocols. No FDA-approved dose exists.

Reconstitution & Storage

Copper-free GHK is supplied as a lyophilized powder, typically in 50 mg or 100 mg vials. Unlike GHK-Cu — which has a characteristic blue-to-turquoise color from the copper coordination — copper-free GHK is a colorless to off-white powder that reconstitutes to a clear, colorless solution.

• Visual identity check — A reconstituted solution that turns blue or turquoise indicates copper coordination (i.e., vial is GHK-Cu, not copper-free GHK). A colorless solution is consistent with the copper-free form. This is one of the simpler at-home identity confirmations for this class.
• Reconstitution — Bacteriostatic water injected slowly down the inside wall of the vial at 45°. Swirl gently — never shake.
• Storage — Lyophilized powder stable at room temperature 12+ months out of light; refrigerated (2–8°C) for longer-term storage. Reconstituted solution refrigerated, used within 28 days.
• In-vivo copper coordination is inevitable — Once injected, copper-free GHK will encounter and bind some endogenous Cu²⁺ in serum and tissue. The product is "copper-free" pre-administration, not in the body.

→ Use the Kalios Dosing Calculator for exact syringe units

Side Effects & Risks

Copper-free GHK has no published human parenteral safety data of its own. The inferred risk profile draws from the GHK-Cu topical record plus specific copper-sequestration considerations.

• Generally well-tolerated in topical / cosmetic GHK-Cu use — Topical GHK-Cu preparations have been used at scale for >25 years with a favorable safety record. Skin irritation in sensitive users is the most commonly reported issue.
• Injection-site reactions (community parenteral use) — Mild local erythema, transient itching, or minor swelling. Generally resolves within hours.
• Theoretical copper-depletion concern at high doses — Because copper-free GHK binds endogenous Cu²⁺ in vivo, very high cumulative doses could theoretically deplete labile copper pools. Clinical significance at typical community doses is likely low but is unquantified.
• Interactions with copper-modulating drugs — Penicillamine and trientine (used for Wilson's disease) are explicit copper chelators; combining with copper-binding GHK is a meaningful interaction requiring medical supervision. Chronic high-dose zinc supplementation (>40 mg/day) depletes copper via intestinal competition and could compound a GHK sequestration effect.
• Theoretical pro-angiogenic / regeneration concern — The GHK family has documented gene-expression modulation that includes regenerative pathways. Like other tissue-repair peptides, this raises a theoretical concern about promoting growth in existing tumors or precancerous tissue — though Pickart and colleagues have also published anti-cancer gene-expression findings, so the net effect is ambiguous. Age-appropriate cancer screening before chronic use is reasonable.
• WADA status — The GHK class is not specifically named on the Prohibited List as of 2026. GHK-Cu has been informally discussed as a candidate for S0 (non-approved substances) evaluation for tested athletes. The copper-free form by analogy would be evaluated similarly. Athletes should not use any GHK form without explicit federation guidance.
• Sourcing risk — identity verification — The most important practical risk. Buyers should confirm via vendor COA (HPLC purity + mass spec) that they are receiving copper-free GHK and not GHK-Cu (or vice versa). The visual color check after reconstitution (blue vs colorless) is a useful adjunct.
• Long-term safety unknown — Zero long-term human safety data exist for parenteral GHK in either form.

Bloodwork & Monitoring

No formal monitoring guideline exists for copper-free GHK. Conservative monitoring mirrors GHK-Cu protocols with attention to copper homeostasis.

• Independent vendor COA review — Mass-spec confirmation that the product is copper-free GHK (and not GHK-Cu mislabeled) is the most important pre-use check.
• Serum copper and ceruloplasmin — Baseline and at 8–12 weeks. Particularly relevant for users on extended high-dose protocols of the copper-free form given its endogenous copper-binding behavior.
• Baseline CMP and CBC — Liver, kidney, and hematological function before starting; repeat at 8 weeks.
• Iron and ferritin — Copper, iron, and zinc share absorption and trafficking pathways. Suboptimal iron status can emerge during copper-modifying interventions.
• Cancer screening (age-appropriate) — Given the broad regenerative gene-expression signature of the GHK family.
• Skin / hair photo documentation — For cosmetic / dermatological endpoints, standardized photographs at 0, 6, and 12 weeks are more reliable than subjective recall.
• Mood / sleep tracking — Given the Bobyntsev rodent anxiolytic literature, subjective mood and sleep changes during a cycle are reasonable endpoints to track.

Commonly Stacked With

→ Check compound compatibility in the Stack Builder

Practical User Notes

• Visual identity check after reconstitution — A blue / turquoise solution indicates copper coordination (you have GHK-Cu, not the copper-free form). A colorless solution is consistent with copper-free GHK. One of the simpler at-home QC checks for this class.
• Mass-spec the vial — For higher confidence, third-party COA with mass spec confirms the specific product identity.
• SubQ near target tissue — For hair-growth applications, intradermal or subcutaneous injection near the hairline is the standard community approach. For systemic effect, abdominal SubQ.
• Topical for cosmetic skin use — A 0.1–2% peptide formulation in an appropriate vehicle (water-based gel or hyaluronic-acid serum) is the standard topical approach. Mostly studied for GHK-Cu, not the copper-free form.
• Conservative dose — 1 mg SubQ daily is a reasonable starting point for community use, with possible up-titration to 2–3 mg if no response and tolerability is good. No clinical evidence supports any specific dose.
• Cycle 8–12 weeks — Longer than typical for repair peptides because dermal / hair cycling is on the order of months. Photographic baseline is the most useful objective tracker.
• Sourcing — identity is the issue — The biggest practical risk is buying GHK-Cu when intending to buy copper-free GHK, or vice versa. Vendors sometimes mislabel. Visual color check + COA review is the practical floor.
• Check copper-zinc balance in routine bloodwork — Particularly for users on extended cycles of copper-free GHK, baseline serum copper, ceruloplasmin, and zinc are reasonable. Avoid concurrent high-dose zinc supplementation that depletes copper.
• Do not combine carelessly with copper-affecting drugs — Penicillamine and trientine are explicit copper chelators used for Wilson's disease; combining with copper-free GHK is a meaningful interaction requiring medical supervision.
• Storage — refrigerate reconstituted — Reconstituted solution at 2–8°C, used within 28 days. Lyophilized powder room temperature out of light.
• Photo documentation — For skin or hair endpoints, standardized photographs at 0, 6, and 12 weeks give objective evidence of change rather than relying on subjective recall, which is heavily placebo-confounded.
• Pregnancy, breastfeeding, history of cancer or Wilson's disease — Conservative contraindications.
• Stop and evaluate — Persistent injection-site reactions, new skin lesions, sustained mood changes, or any unexplained new symptom.

Regulatory Status

Related Compounds

People researching the GHK-Cu Fragment often also look at these:

Next Steps

Key References

1. Pickart L, Thaler MM. Tripeptide in human serum which prolongs survival of normal liver cells and stimulates growth in neoplastic liver. Nat New Biol. 1973;243(124):85-87. PMID: 4351857. (Original peer-reviewed report — isolation of GHK from human plasma.)
2. Maquart FX, Pickart L, Laurent M, Gillery P, Monboisse JC, Borel JP. Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu²⁺. FEBS Lett. 1988;238(2):343-346. PMID: 3169264. (Foundational copper-bound collagen-stimulation paper.)
3. Choi HR, Kang YA, Ryoo SJ, Shin JW, Na JI, Huh CH, Park KC. Stem cell recovering effect of copper-free GHK in skin. J Pept Sci. 2012;18(11):685-690. doi:10.1002/psc.2455. (Key paper for the copper-free form: stem-cell preservation in human skin-equivalent models without copper coordination.)
4. Pickart L, Vasquez-Soltero JM, Margolina A. The human tripeptide GHK-Cu in prevention of oxidative stress and degenerative conditions of aging. Oxid Med Cell Longev. 2012;2012:324832. PMID: 22666521.
5. Pickart L, Vasquez-Soltero JM, Margolina A. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. Biomed Res Int. 2015;2015:648108. PMID: 26236730.
6. Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. Int J Mol Sci. 2018;19(7):1987. PMID: 29986520. (Comprehensive review noting copper-free findings.)
7. Pickart L, Vasquez-Soltero JM, Pickart FD, Majnarich J. GHK, the Human Skin Remodeling Peptide, Induces Anti-Cancer Expression of Numerous Caspase, Growth Regulatory, and DNA Repair Genes. J Anal Oncol. 2014;3(2):79-87.
8. Beretta G, Aldini G, Facino RM, Russell RM, Krinsky NI, Yeum KJ. Glycyl-histidyl-lysine (GHK) is a quencher of α,β-4-Hydroxy-trans-2-nonenal: a comparison with carnosine. Chem Res Toxicol. 2007;20(9):1309-1314. doi:10.1021/tx700185s. (Copper-independent aldehyde sequestration.)
9. Beretta G, Arlandini E, Artali R, Anton JM, Maffei Facino R. Acrolein sequestering ability of the endogenous tripeptide glycyl-histidyl-lysine (GHK). J Pharm Biomed Anal. 2008;47(3):596-602.
10. Trapaidze A, Hureau C, Bal W, Winterhalter M, Faller P. Thermodynamic study of Cu²⁺ binding to the DAHK and GHK peptides by isothermal titration calorimetry (ITC) with the weaker competitor glycine. J Biol Inorg Chem. 2012;17(1):37-47. PMID: 21748269. (Quantifies very high copper-binding affinity driving in-vivo coordination after administration.)
11. Pickart L, Freedman JH, Loker WJ, Peisach J, Perkins CM, Stenkamp RE, Weinstein B. Growth-modulating plasma tripeptide may function by facilitating copper uptake into cells. Nature. 1980;288(5792):715-717. PMID: 7432330.
12. Pickart L, Vasquez-Soltero JM, Margolina A. The Effect of the Human Peptide GHK on Gene Expression Relevant to Nervous System Function and Cognitive Decline. Brain Sci. 2017;7(2):20. PMID: 28212278.
13. Pollard JD, Quan S, Kang T, Koch RJ. Effects of copper tripeptide on the growth and expression of growth factors by normal and irradiated fibroblasts. Arch Facial Plast Surg. 2005;7(1):27-31. PMID: 15655171.
14. Kang YA, Choi HR, Na JI, Huh CH, Kim MJ, Youn SW, Kim KH, Park KC. Copper-GHK increases integrin expression and p63 positivity by keratinocytes. Arch Dermatol Res. 2009;301(4):301-306. PMID: 19129717.
15. Hostynek JJ, Dreher F, Maibach HI. Human skin penetration of a copper tripeptide in vitro as a function of skin layer. Inflamm Res. 2011;60(1):79-86. PMID: 20835751.
16. Gruchlik A, Jurzak M, Chodurek E, Dzierzewicz Z. Effect of Gly-Gly-His, Gly-His-Lys and their copper complexes on TNF-alpha-dependent IL-6 secretion in normal human dermal fibroblasts. Acta Pol Pharm. 2012;69(6):1303-1306. PMID: 23285693.
17. FDA. Bulk Drug Substances Nominated for Use in Compounding — 503A and 503B Categories. FDA.gov. Updated 2025-2026.
18. WADA Prohibited List 2026. World Anti-Doping Agency. wada-ama.org.